Condition: Chronic Inflammatory Demyelinating Polyneuropathy · Sponsor: Dianthus Therapeutics
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
This description comes directly from the study's public registry record.
Dianthus Clinical Contact Center · 929-999-4055 · clinicaltrials@dianthustx.com
Always discuss trial participation with your own doctor first.
| Clinical Study Site | Birmingham, Alabama, United States | Recruiting |
| Clinical Study Site | Phoenix, Arizona, United States | Recruiting |
| Clinical Study Site | Scottsdale, Arizona, United States | Recruiting |
| Clinical Study Site | Los Angeles, California, United States | Recruiting |
| Clinical Study Site | San Francisco, California, United States | Recruiting |
| Clinical Study Site | San Francisco, California, United States | Recruiting |
| Cinical Study Site | New Haven, Connecticut, United States | Recruiting |
| Clinical Study Site | Washington D.C., District of Columbia, United States | Recruiting |
| Clinical Study Site | Maitland, Florida, United States | Recruiting |
| Clinical Study Site | Tampa, Florida, United States | Recruiting |
| Clinical Study Site | Honolulu, Hawaii, United States | Recruiting |
| Clinical Study Site | Chicago, Illinois, United States | Recruiting |
+ 168 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06858579